Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans

Leif C. Groop, Nir Barzilai, Klaus Ratheiser, Livio Luzi, Elisabeth Wåhlin-Boll, Arne Melander, Ralph A. DeFronzo

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objective: To examine the relationship between plasma glyburide concentrations (0, 50, 100, 200, 400, and 800 nM) and the insulin response and glucose metabolism during euglycemic (4.6 ± 0.1 mM) and hyperglycemic (11.6 ± 0.2 mM) conditions. Research Design and Methods: Nine healthy subjects participated in the study. Steady-state plasma glyburide concentrations were achieved by primed continuous intravenous infusion of glyburide. Results: During both euglycemia and hyperglycemia, glyburide enhanced insulin secretion and glucose disposal only to drug levels of 100-200 nM corresponding to an oral dose ≤10 mg. Conclusions: The data suggest that glyburide (and probably other sulfonylureas) operates within a narrow range of plasma concentrations (50-200 nM), which can be achieved with very low doses of the drug. It remains to be shown whether the threshold of maximal effect also in clinical practice is achieved with lower sulfonylurea doses than that currently used.

Original languageEnglish (US)
Pages (from-to)724-727
Number of pages4
JournalDiabetes Care
Volume14
Issue number8
StatePublished - Aug 1991
Externally publishedYes

Fingerprint

Glyburide
Insulin
Glucose
Intravenous Infusions
Hyperglycemia
Pharmaceutical Preparations
Healthy Volunteers
Research Design

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Groop, L. C., Barzilai, N., Ratheiser, K., Luzi, L., Wåhlin-Boll, E., Melander, A., & DeFronzo, R. A. (1991). Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care, 14(8), 724-727.

Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. / Groop, Leif C.; Barzilai, Nir; Ratheiser, Klaus; Luzi, Livio; Wåhlin-Boll, Elisabeth; Melander, Arne; DeFronzo, Ralph A.

In: Diabetes Care, Vol. 14, No. 8, 08.1991, p. 724-727.

Research output: Contribution to journalArticle

Groop, LC, Barzilai, N, Ratheiser, K, Luzi, L, Wåhlin-Boll, E, Melander, A & DeFronzo, RA 1991, 'Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans', Diabetes Care, vol. 14, no. 8, pp. 724-727.
Groop LC, Barzilai N, Ratheiser K, Luzi L, Wåhlin-Boll E, Melander A et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care. 1991 Aug;14(8):724-727.
Groop, Leif C. ; Barzilai, Nir ; Ratheiser, Klaus ; Luzi, Livio ; Wåhlin-Boll, Elisabeth ; Melander, Arne ; DeFronzo, Ralph A. / Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. In: Diabetes Care. 1991 ; Vol. 14, No. 8. pp. 724-727.
@article{a51c78901f924739878a75fe4ce6cc39,
title = "Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans",
abstract = "Objective: To examine the relationship between plasma glyburide concentrations (0, 50, 100, 200, 400, and 800 nM) and the insulin response and glucose metabolism during euglycemic (4.6 ± 0.1 mM) and hyperglycemic (11.6 ± 0.2 mM) conditions. Research Design and Methods: Nine healthy subjects participated in the study. Steady-state plasma glyburide concentrations were achieved by primed continuous intravenous infusion of glyburide. Results: During both euglycemia and hyperglycemia, glyburide enhanced insulin secretion and glucose disposal only to drug levels of 100-200 nM corresponding to an oral dose ≤10 mg. Conclusions: The data suggest that glyburide (and probably other sulfonylureas) operates within a narrow range of plasma concentrations (50-200 nM), which can be achieved with very low doses of the drug. It remains to be shown whether the threshold of maximal effect also in clinical practice is achieved with lower sulfonylurea doses than that currently used.",
author = "Groop, {Leif C.} and Nir Barzilai and Klaus Ratheiser and Livio Luzi and Elisabeth W{\aa}hlin-Boll and Arne Melander and DeFronzo, {Ralph A.}",
year = "1991",
month = "8",
language = "English (US)",
volume = "14",
pages = "724--727",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans

AU - Groop, Leif C.

AU - Barzilai, Nir

AU - Ratheiser, Klaus

AU - Luzi, Livio

AU - Wåhlin-Boll, Elisabeth

AU - Melander, Arne

AU - DeFronzo, Ralph A.

PY - 1991/8

Y1 - 1991/8

N2 - Objective: To examine the relationship between plasma glyburide concentrations (0, 50, 100, 200, 400, and 800 nM) and the insulin response and glucose metabolism during euglycemic (4.6 ± 0.1 mM) and hyperglycemic (11.6 ± 0.2 mM) conditions. Research Design and Methods: Nine healthy subjects participated in the study. Steady-state plasma glyburide concentrations were achieved by primed continuous intravenous infusion of glyburide. Results: During both euglycemia and hyperglycemia, glyburide enhanced insulin secretion and glucose disposal only to drug levels of 100-200 nM corresponding to an oral dose ≤10 mg. Conclusions: The data suggest that glyburide (and probably other sulfonylureas) operates within a narrow range of plasma concentrations (50-200 nM), which can be achieved with very low doses of the drug. It remains to be shown whether the threshold of maximal effect also in clinical practice is achieved with lower sulfonylurea doses than that currently used.

AB - Objective: To examine the relationship between plasma glyburide concentrations (0, 50, 100, 200, 400, and 800 nM) and the insulin response and glucose metabolism during euglycemic (4.6 ± 0.1 mM) and hyperglycemic (11.6 ± 0.2 mM) conditions. Research Design and Methods: Nine healthy subjects participated in the study. Steady-state plasma glyburide concentrations were achieved by primed continuous intravenous infusion of glyburide. Results: During both euglycemia and hyperglycemia, glyburide enhanced insulin secretion and glucose disposal only to drug levels of 100-200 nM corresponding to an oral dose ≤10 mg. Conclusions: The data suggest that glyburide (and probably other sulfonylureas) operates within a narrow range of plasma concentrations (50-200 nM), which can be achieved with very low doses of the drug. It remains to be shown whether the threshold of maximal effect also in clinical practice is achieved with lower sulfonylurea doses than that currently used.

UR - http://www.scopus.com/inward/record.url?scp=0025883121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025883121&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 724

EP - 727

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 8

ER -